Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.CALC · Entity 7804 | Director | October 01, 2026 | October 05, 2026 |
| VIVUS INCVVUS · Entity 151460 | Director | October 26, 2018 | October 29, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2036-09-30 | Direct | 20,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 20,000 · Balance 20,000 F1: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.
VIVUS INC
Report date October 26, 2018 · Filed October 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.53 | Direct | 15,000 |
Reported balance
After 2018-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-10-26 · Grant · Acquired 15,000 · Balance 15,000 F1: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the 26th of each month following October 26, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates. F2: The option expires on the earlier of (a) October 26, 2025 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider. |
Filing footnotes · ownership attribution and instrument terms
F1: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the 26th of each month following October 26, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates.
F2: The option expires on the earlier of (a) October 26, 2025 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Onconetix, Inc.
Report date August 19, 2022 · Filed August 23, 2022
Section 16 reporting ended · disclosed 2022-08-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-19 · Tax withholding · Acquired 29,636 · Balance 29,636 Row 2 · 2022-08-19 · Sale · Disposed 29,636 · Balance 0 F1: The Common Stock reported herein were sold by the reporting person at a high price of $4.02, a low price of $3.91 and an average price of $3.94 per share of Common Stock. Upon request, the reporting person will provide details of each sale. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2030-01-14 | Direct | 16,284 |
Reported balance
After 2022-08-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-19 · Tax withholding · Disposed 29,636 · Balance 16,284 |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock reported herein were sold by the reporting person at a high price of $4.02, a low price of $3.91 and an average price of $3.94 per share of Common Stock. Upon request, the reporting person will provide details of each sale.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2016 Filed Oct 18, 2016 16:40 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionCommon Stock | 1,389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-16-002869 · edgar.xml · nonDerivative · entry 1 Shaw Allan · CIK 0001626850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 17:03 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionRestricted Stock Units · Derivative | 1,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-16-002756 · edgar.xml · derivative · entry 3 Shaw Allan · CIK 0001626850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,335 Underlying: Common Stock · 1,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. F3 · derivative.exercise_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016, and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates. F3 · derivative.expiration_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016, and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 17:03 UTC | VIVUS INC VVUS · Entity 151460 | Disposition to issuerCommon Stock | 540 | $1.06 | $572.40 |
DisclosureSEC source: 0001123292-16-002756 · edgar.xml · nonDerivative · entry 2 Shaw Allan · CIK 0001626850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,188 F2 · kind: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 17:03 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionCommon Stock | 1,389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-16-002756 · edgar.xml · nonDerivative · entry 1 Shaw Allan · CIK 0001626850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.